Dr. Reddy’s Laboratories launched a generic version of bosutinib in the United States, offering a lower-cost alternative to Pfizer’s oncology therapy used in certain leukemia cases. The Hyderabad-based firm said shipments began following regulatory clearance for its abbreviated new drug application pathway.
Generic entry typically reduces out-of-pocket costs for patients under commercial insurance and Medicare, though physicians must monitor bioequivalence and switching protocols. Hospital formularies often add generics after brief review committees.
The launch strengthens Dr. Reddy’s presence in oncology portfolios that include both small molecules and biosimilars. Patent litigation landscapes determine whether additional competitors arrive quickly or enjoy limited exclusivity windows.
Patient advocacy groups welcomed affordability gains while urging continued investment in novel targeted therapies for resistant disease variants.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.thehindu.com/business/Industry/dr-reddys-launches-generic-cancer-drug-bosutinib-in-us/article71097328.ece